

# Jiawen Qian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8994743/publications.pdf>

Version: 2024-02-01

13  
papers

503  
citations

1040056

9  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

968  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Advances in Brain Delivery Systems Based on Biomimetic Nanoparticles. <i>ChemNanoMat</i> , 2022, 8, .   | 2.8 | 4         |
| 2  | Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2801-2814.   | 4.2 | 3         |
| 3  | TLR1/TLR2 signaling blocks the suppression of monocytic myeloid-derived suppressor cell by promoting its differentiation into M1-type macrophage. <i>Molecular Immunology</i> , 2019, 112, 266-273.   | 2.2 | 32        |
| 4  | Identification and immunological evaluation of novel TLR2 agonists through structure optimization of Pam3CSK4. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2784-2800.   | 3.0 | 12        |
| 5  | MicroRNA 15a/16 $\hat{=}$ 1 suppresses aryl hydrocarbon receptor $\hat{=}$ dependent interleukin $\hat{=}$ 22 secretion in CD4+ T cells and contributes to immune $\hat{=}$ mediated organ injury. <i>Hepatology</i> , 2018, 67, 1027-1040. | 7.3 | 22        |
| 6  | The IFN- $\hat{=}$ 3/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. <i>Journal of Neuroinflammation</i> , 2018, 15, 290.  | 7.2 | 177       |
| 7  | Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1777-1788.             | 4.2 | 67        |
| 8  | Fc $\hat{=}$ u Receptor Promotes the Survival and Activation of Marginal Zone B Cells and Protects Mice against Bacterial Sepsis. <i>Frontiers in Immunology</i> , 2018, 9, 160.  | 4.8 | 13        |
| 9  | TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia. <i>Cancer Immunology Research</i> , 2018, 6, 1220-1233.  | 3.4 | 64        |
| 10 | MiR $\hat{=}$ 15a/16 deficiency enhances anti $\hat{=}$ tumor immunity of glioma $\hat{=}$ infiltrating CD8+ T cells through targeting mTOR. <i>International Journal of Cancer</i> , 2017, 141, 2082-2092.                                 | 5.1 | 67        |
| 11 | Biological Response Modifier in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 69-138.   | 1.6 | 8         |
| 12 | Low percentage of CD24 $\hat{=}$ hiCD27+CD19+ B cells decelerates gastric cancer progression in XELOX-treated patients. <i>International Immunopharmacology</i> , 2015, 26, 322-327.  | 3.8 | 7         |
| 13 | Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. <i>Clinical Immunology</i> , 2014, 154, 26-36.   | 3.2 | 25        |